Literature DB >> 16283181

PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- for.

Kazunari Ishii1, Satoshi Minoshima.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16283181     DOI： 10.1007/s00259-005-1936-3

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  30 in total

1.  Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease?

Authors:  G Chételat; B Desgranges; V de la Sayette; F Viader; F Eustache; J-C Baron
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

2.  Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET.

Authors:  K Herholz; E Salmon; D Perani; J C Baron; V Holthoff; L Frölich; P Schönknecht; K Ito; R Mielke; E Kalbe; G Zündorf; X Delbeuck; O Pelati; D Anchisi; F Fazio; N Kerrouche; B Desgranges; F Eustache; B Beuthien-Baumann; C Menzel; J Schröder; T Kato; Y Arahata; M Henze; W D Heiss
Journal:  Neuroimage       Date:  2002-09       Impact factor: 6.556

3.  Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease.

Authors:  Karl Herholz; Helge Schopphoff; Mathias Schmidt; Rüdiger Mielke; Wolfgang Eschner; Klemens Scheidhauer; Harald Schicha; Wolf-Dieter Heiss; Klaus Ebmeier
Journal:  J Nucl Med       Date:  2002-01       Impact factor: 10.057

4.  Alzheimer disease: improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections.

Authors:  J H Burdette; S Minoshima; T Vander Borght; D D Tran; D E Kuhl
Journal:  Radiology       Date:  1996-03       Impact factor: 11.105

5.  Tc-99m ethyl cysteinate dimer SPECT and 2-[F-18]fluoro-2-deoxy-D-glucose PET in Alzheimer's disease. Comparison of perfusion and metabolic patterns.

Authors:  K Ishii; M Sasaki; S Sakamoto; S Yamaji; H Kitagaki; E Mori
Journal:  Clin Nucl Med       Date:  1999-08       Impact factor: 7.794

6.  Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve.

Authors:  L Mosconi; K Herholz; I Prohovnik; B Nacmias; M T R De Cristofaro; M Fayyaz; L Bracco; S Sorbi; A Pupi
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-01       Impact factor: 10.154

7.  Statistical brain mapping of 18F-FDG PET in Alzheimer's disease: validation of anatomic standardization for atrophied brains.

Authors:  K Ishii; F Willoch; S Minoshima; A Drzezga; E P Ficaro; D J Cross; D E Kuhl; M Schwaiger
Journal:  J Nucl Med       Date:  2001-04       Impact factor: 10.057

8.  Regional cerebral blood flow assessed with 99mTc-ECD SPET as a marker of progression of mild cognitive impairment to Alzheimer's disease.

Authors:  Marta Encinas; Ramón De Juan; Alberto Marcos; Pedro Gil; Ana Barabash; Cristina Fernández; Carmen De Ugarte; José Antonio Cabranes
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-15       Impact factor: 9.236

9.  Altered PET functional brain responses in cognitively intact elderly persons at risk for Alzheimer disease (carriers of the epsilon4 allele).

Authors:  Nikolaos Scarmeas; Christian Habeck; Karen E Anderson; John Hilton; Davangere P Devanand; Gregory H Pelton; Matthias H Tabert; Joseph Flynn; Aileen Park; Alejandra Ciappa; Benjamin Tycko; Yaakov Stern
Journal:  Am J Geriatr Psychiatry       Date:  2004 Nov-Dec       Impact factor: 4.105

10.  MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.

Authors:  L Mosconi; D Perani; S Sorbi; K Herholz; B Nacmias; V Holthoff; E Salmon; J-C Baron; M T R De Cristofaro; A Padovani; B Borroni; M Franceschi; L Bracco; A Pupi
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910
View more
  3 in total

1.  Computer-assisted diagnostic system for neurodegenerative dementia using brain SPECT and 3D-SSP.

Authors:  Kazunari Ishii; Tomonori Kanda; Takafumi Uemura; Naokazu Miyamoto; Toshiki Yoshikawa; Kenichi Shimada; Shingo Ohkawa; Satoshi Minoshima
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-16       Impact factor: 9.236

Review 2.  Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease.

Authors:  Roberta Diaz Brinton
Journal:  Adv Drug Deliv Rev       Date:  2008-07-04       Impact factor: 15.470

Review 3.  Radiopharmaceuticals for positron emission tomography investigations of Alzheimer's disease.

Authors:  Kjell Någren; Christer Halldin; Juha O Rinne
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12-22       Impact factor: 9.236
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.